Xtl Biopharmaceuticals XTLB
NASDAQ XTLB
$1.94 -0.02 (-1.02%)
As of: Oct 20, 2026 · 3:58 PM EDT

Xtl Biopharmaceuticals (XTLB) Cost of Revenue (2011 - 2024)

Updated

Xtl Biopharmaceuticals (XTLB) posted Cost of Revenue of $448,000 for the year ended Dec 31, 2025, unchanged from $448,000 a year earlier.

Analysis

Xtl Biopharmaceuticals (XTLB) Cost of Revenue (2011 - 2024) Analysis & Trends

Since the year ended Dec 31, 2010, Xtl Biopharmaceuticals has reported Cost of Revenue for 6 years.

  • Business Quant data shows XTLB's Cost of Revenue at $448,000 in the year ended Dec 31, 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cost of Rev (Qtr)
1 Eli Lilly 1,146.94 Bn 1,115.53 Bn 19.71 Bn 3.27 Bn
2 Johnson & Johnson 624.96 Bn 543.49 Bn 17.26 Bn 8.05 Bn
3 AbbVie 510.15 Bn 483.27 Bn 12.70 Bn 4.29 Bn
4 Merck 366.13 Bn 320.51 Bn 12.21 Bn 4.40 Bn
5 Novartis Ag 297.75 Bn 261.74 Bn 11.24 Bn 3.71 Bn
6 Astrazeneca 261.93 Bn 235.62 Bn 12.86 Bn 2.52 Bn
7 Amgen 236.51 Bn 191.91 Bn 7.24 Bn 2.81 Bn
8 Gilead Sciences 194.27 Bn 168.47 Bn 6.22 Bn 1.58 Bn
9 Pfizer 171.74 Bn 118.39 Bn 10.94 Bn 4.09 Bn
10 Xtl Biopharmaceuticals 18.55 Mn 15.35 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 332,000.00
Sep 30, 2014 121,000.00
Jun 30, 2014 113,000.00
Mar 31, 2014 157,000.00
Dec 31, 2013 174,000.00
Sep 30, 2013 180,000.00
Jun 30, 2013 188,000.00
Mar 31, 2013 199,000.00
Dec 31, 2012 224,000.00
Sep 30, 2012 156,000.00
Jun 30, 2012 201,000.00
Mar 31, 2012 250,000.00
Dec 31, 2011 158,000.00
Sep 30, 2011 170,000.00
Jun 30, 2011 256,000.00
API Access

Xtl Biopharmaceuticals Cost of Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cost-of-revenue&ticker=XTLB&period=max&api_key=YOUR_API_KEY